Skip to main content
    A

    Atrium Therapeutics, Inc. Common Stock (RNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.51
    +0.01 (+0.13%)

    Market Cap: $162.00M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Atrium Therapeutics, Inc. Common Stock (RNA) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Atrium Therapeutics, Inc. Common Stock reported EPS of -$0.25, above the -$1.15 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    52%(14/27)
    Avg Surprise
    -8.00%
    Streak
    1 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$1.26
    Range-$1.72 - -$0.39
    6 analysts
    Revenue Consensus
    $404.00K
    RangeN/A
    6 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$1.43
    Range-$1.57 - -$1.28
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.44+1.0%
    60d ago-$1.98+28.0%
    30d ago-$1.98+28.0%
    7d ago-$1.57+9.2%
    Current-$1.43
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts

    Next Report

    RNA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    Earnings History

    Of the 31 quarters below that had an estimate, RNA beat 17, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $15.32M, up 22.9% from $12.47M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.25-$1.15N/A+78.26%BeatN/A21 up, 0 downNov 12, 2026$15.32M
    Jun 30, 2026-$1.18-$0.64-$0.64 - -$0.64-84.38%MissN/A10 up, 0 downAug 13, 2026$3.00M
    Mar 31, 2026-$0.97-$1.05-$1.05 - -$1.05+7.62%BeatN/A10 up, 0 downMay 14, 2026$19.64M
    Dec 31, 2025-$1.59-$1.26-$1.44 - -$0.96-26.19%MissN/A110 up, 1 downFeb 26, 2026$859000
    Sep 30, 2025-$1.27-$1.10-$1.27 - -$0.61-15.45%MissN/A132 up, 0 downNov 10, 2025$12.47M
    Jun 30, 2025-$1.21-$0.96-$1.33 - -$0.55-26.04%MissN/A157 up, 3 downAug 7, 2025$3.85M
    Mar 31, 2025-$0.90-$0.88-$1.07 - -$0.55-2.27%MissN/A110 up, 1 downMay 8, 2025$1.57M
    Dec 31, 2024-$0.80-$0.78-$0.90 - -$0.57-2.45%MissN/A95 up, 4 downFeb 26, 2025$2.97M
    Sep 30, 2024-$0.65-$0.72-$0.94 - -$0.46+9.72%BeatN/A101 up, 0 downNov 7, 2024$2.34M
    Jun 30, 2024-$0.65-$0.78-$0.94 - -$0.60+16.67%BeatN/A80 up, 0 downAug 9, 2024$2.04M
    Mar 31, 2024-$0.79-$0.88-$0.95 - -$0.67+10.23%BeatN/A70 up, 0 downMay 9, 2024$3.54M
    Dec 31, 2023-$0.79-$0.66-$0.88 - $0.07-19.70%MissN/A60 up, 0 downFeb 28, 2024$2.19M
    Sep 30, 2023-$0.71-$0.75-$0.80 - -$0.73+5.33%BeatN/A50 up, 0 downNov 8, 2023$2.82M
    Jun 30, 2023-$0.66-$0.79-$0.88 - -$0.73+16.46%BeatN/A70 up, 0 downAug 8, 2023$2.32M
    Mar 31, 2023-$0.74-$0.86-$1.05 - -$0.69+13.95%BeatN/A70 up, 0 downMay 9, 2023$2.23M
    Dec 31, 2022-$0.88-$0.89-$1.07 - -$0.75+1.12%BeatN/A70 up, 0 downFeb 28, 2023$2.77M
    Sep 30, 2022-$0.82-$0.93-$1.00 - -$0.84+11.83%BeatN/A70 up, 0 downNov 8, 2022$2.48M
    Jun 30, 2022-$0.92-$0.77-$0.84 - -$0.67-19.48%MissN/A70 up, 0 downAug 9, 2022$2.18M
    Mar 31, 2022-$0.71-$0.83-$1.00 - -$0.60+14.46%BeatN/A50 up, 0 downMay 10, 2022$1.79M
    Dec 31, 2021-$0.82-$0.70-$0.73 - -$0.63-17.14%MissN/A40 up, 0 downMar 1, 2022$1.85M
    Sep 30, 2021-$0.68-$0.68-$0.76 - -$0.600.00%In lineN/A4N/ANov 9, 2021$2.16M
    Jun 30, 2021-$0.70-$0.71-$0.84 - -$0.63+1.41%BeatN/A4N/AAug 9, 2021$2.61M
    Mar 31, 2021-$0.64-$0.56-$0.63 - -$0.47-14.29%MissN/A3N/AMay 12, 2021$2.70M
    Dec 31, 2020-$0.43-$0.34-$0.38 - -$0.29-26.47%MissN/A4N/AMar 15, 2021$2.14M
    Sep 30, 2020-$0.31-$0.43-$0.55 - -$0.27+27.91%BeatN/A4N/ANov 10, 2020$1.75M
    Jun 30, 2020-$1.23-$0.36N/A-241.67%MissN/AN/AN/AAug 10, 2020$1.54M
    Mar 31, 2020-$0.56-$1.58N/A+64.56%BeatN/AN/AN/AJun 8, 2020$1.36M
    Sep 30, 2014-$0.29-$0.23N/A-26.09%MissN/AN/AN/ASep 30, 2014N/A
    Jun 30, 2014-$0.22-$0.25N/A+12.00%BeatN/AN/AN/AJun 30, 2014$164000
    Mar 31, 2014$0.19-$0.03N/A+733.33%BeatN/AN/AN/AMar 31, 2014$20.65M
    Dec 31, 2013-$0.11-$0.12N/A+8.33%BeatN/AN/AN/ADec 31, 2013$3.64M
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$4.97, after -$2.89 the year before. It was -$0.11 for the year ended Dec 31, 2013, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$4.97N/A
    Dec 31, 2024-$2.89N/A
    Dec 31, 2023-$2.90N/A
    Dec 31, 2022-$3.33N/A
    Dec 31, 2021-$2.84N/A
    Dec 31, 2020-$2.85N/A
    Dec 31, 2013-$0.11N/A

    Frequently Asked Questions About RNA

    Did RNA beat earnings estimates last quarter?

    Yes. Atrium Therapeutics, Inc. Common Stock reported EPS of -$0.25 for the quarter ended Sep 30, 2026, above the -$1.15 estimate, a 78.26% surprise.

    What EPS do analysts expect from RNA next quarter?

    The consensus EPS estimate for Atrium Therapeutics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$1.26 from 6 analysts, with estimates from -$1.72 to -$0.39.

    How often does RNA beat earnings estimates?

    Atrium Therapeutics, Inc. Common Stock beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -8.86%.